Reston, VA (August 29, 2025)—New research has been published ahead-of-print by The Journal of Nuclear Medicine (JNM). JNM is published by the Society of Nuclear Medicine and Molecular Imaging, an international scientific and medical organization dedicated to advancing nuclear medicine, molecular imaging, and theranostics—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Summaries of the newly published research articles are provided below.
Advancing PET/CT Imaging with Continuous Bed Motion
A new study explored how ultrahigh sensitivity and continuous bed motion affect image quality in total-body PET/CT scans. Using phantom tests and patient scans, researchers found minimal trade-offs in recovery coefficients and resolution, while maintaining strong correlations in lesion and tissue metrics, supporting faster, more comprehensive imaging.
Tracking Immune Cells During COVID-19 with PET Imaging
Researchers developed a nanobody-based PET tracer to monitor myeloid cell activity during SARS-CoV-2 infection in macaques. The tracer revealed dynamic changes in lymph nodes, spleen, and bone marrow, offering a new way to visualize immune responses and inflammation beyond the lungs throughout the course of infection.
New PET Imaging Tracer Tested in Thyroid and Neuroendocrine Tumors
A pilot study evaluated a novel PET tracer, ⁶⁸Ga-DOTA-MGS5, targeting CCK2 receptors in patients with medullary thyroid cancer (MTC) and other neuroendocrine tumors (NETs). Results showed strong lesion detection and uptake in MTC and bronchopulmonary NETs, though its value appeared limited for gastroenteropancreatic NETs.
Targeting CD70 in Burkitt Lymphoma with a New PET Tracer
Scientists developed a CD70-specific PET tracer, ⁴⁴Sc-CHX-A″-DTPA-RCCB6, to improve imaging in Burkitt lymphoma. Tested in cell and animal models, the tracer showed strong, selective uptake in CD70-rich tumors while sparing low-expressing ones. These findings suggest a promising tool for advancing diagnosis and therapy monitoring in lymphoma.
Combining PSMA Radiotherapy and Immunotherapy in Prostate Cancer
Prostate cancer treatment with ¹⁷⁷Lu-PSMA-617 has improved survival, but many patients develop resistance. This review examines how pairing PSMA-targeted radiopharmaceutical therapy with immune checkpoint inhibitors could boost treatment responses, outlining current preclinical and clinical evidence and highlighting future strategies to overcome prostate cancer's immunosuppressive environment.
Visit the JNM website for the latest research, and follow our new Twitter and Facebook pages @JournalofNucMed or follow us on LinkedIn .
